
The Union Health Ministry proposed amendments to the Drugs Rules, 1945, to immediately suspend manufacturing licences for drugs declared Not of Standard Quality on critical parameters.
The suspension by the Central or State Licensing Authority will require manufacturers to perform root cause analysis and implement CAPA before revocation.
Consequential amendments to Form 13 will endorse the Government Analyst's report to the DCGI, concerned licensing authorities, manufacturers, and marketers.